Sise Meghan E, Wisocky Jessica, Rosales Ivy A, Chute Donald, Holmes Jacinta A, Corapi Kristin M, Babitt Jodie L, Tangren Jessica S, Hashemi Nikroo, Lundquist Andrew L, Williams Winfred W, Mount David B, Andersson Karin L, Rennke Helmut G, Smith R Neal, Colvin Robert, Thadhani Ravi I, Chung Raymond T
Division of Nephrology, Department of Medicine, Massachusetts General Hospital, Boston, MA.
Gastrointestinal Unit, Department of Medicine, Massachusetts General Hospital, Boston, MA.
Kidney Int Rep. 2016 Sep;1(3):135-143. doi: 10.1016/j.ekir.2016.06.006.
Novel, all-oral interferon-free direct-acting antiviral agents have revolutionized the management of hepatitis C virus (HCV) infection by producing exceptional cure rates with minimal adverse events. While provocation or exacerbation of autoimmunity has been reported in HCV-infected patients receiving interferon, this phenomenon has not been reported in patients receiving interferon-free HCV therapy. We report the occurrence of three cases of lupus-like immune complex-mediated glomerulonephritis occurring shortly after exposure to sofosbuvir-based direct-acting antiviral therapies. In all three cases, renal function quickly improved with immunosuppression. However, two of the three patients developed infectious complications of immunosuppression and died. This is the first report of a lupus-like immune complex mediated glomerulonephritis occurring in the context of HCV eradication with all-oral direct-acting antiviral therapies.
新型的、全口服且不含干扰素的直接抗病毒药物彻底改变了丙型肝炎病毒(HCV)感染的治疗方式,治愈率极高且不良事件极少。虽然在接受干扰素治疗的HCV感染患者中曾有自身免疫激发或加重的报道,但在接受不含干扰素的HCV治疗的患者中尚未有此现象的报道。我们报告了3例在接受基于索磷布韦的直接抗病毒治疗后不久发生的狼疮样免疫复合物介导的肾小球肾炎病例。在所有3例病例中,免疫抑制治疗后肾功能迅速改善。然而,3例患者中有2例出现了免疫抑制的感染并发症并死亡。这是首例关于在使用全口服直接抗病毒疗法根除HCV的背景下发生狼疮样免疫复合物介导的肾小球肾炎的报告。